Expanding role of bisphosphonates in the management of early breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1051-1054

  Higgins, Michaela J ^a   Park, Ben H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Ovarian suppression; Tamoxifen; Zoledronic acid

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; FEEDBACK SYSTEM; HUMAN; HYPOTHALAMUS; HYPOTHESIS; METASTASIS; MICROENVIRONMENT; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW;

EID: 70350623063     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.70     Document Type: Review

References (21)

1. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(7), 679-691 (2009). •• Largest randomized trial to date of adjuvant zoledronic acid in premenopausal early breast cancer. Compared with endocrine therapy alone, endocrine therapy plus zoledronic acid was associated with a significantly improved disease-free survival rate.
2. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol. 15(3), 955-962 (1997). (Pubitemid 27106277)
3. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341-1347 (1997). (Pubitemid 27167365)
4. Shapiro CL,Halabi S, Gibson G. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J. Clin. Oncol. 26(Suppl. 20), (2008) (Abstract 512).
5. Brufsky A, Bundred N, Coleman R et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5), 503-514 (2008). (Pubitemid 351304583)
6. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321), 1929-1936 (2002).
7. Gnant M, Mlineritsch B, Luschin- Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9(9), 840-849 (2008).
8. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates: the experience of the national cancer institute of Milan. Ann. Oncol. 20(1), 137-145 (2009).
9. Coleman RE. Bisphosphonates: clinical experience. Oncologist 9(Suppl. 4), 14-27 (2004).
10. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 15(1), 57-62 (2005).
11. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 328(3), 679-687 (2005). (Pubitemid 40208305)
12. Santini D, Vincenzi B, Avvisati G et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8(5), 1080-1084 (2002). (Pubitemid 34517643)
13. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84(8), 1126-1134 (2001).
14. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br. J. Cancer 96(12), 1796 - 1801 (2007).
15. Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 47(4), 740-746 (2008). (Pubitemid 351878444)
16. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst. 99(4), 322-330 (2007). (Pubitemid 47073494)
17. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl Cancer Inst. 100(16), 1167-1178 (2008).
18. Burkinshaw R, Thorpe H, Pollard S et al. The AZURE trial-does adjuvant zoledronic acid reduce recurrence in patients with high-risk localized breast cancer? Bone 38(Suppl. 1), 70-71 (2006).
19. Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ, Coleman RE. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer. In: San Antonio Breast Cancer Symposium. (Eds). San Antonio, (2008) (Abstract 5101).
20. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005). (Pubitemid 43016814)
21. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).